Sab Biotherapeutics Inc SABS

$3.12 -0.18 (-5.45%)

Valuation

Market cap
300,254,000
Revenue TTM
$0
Net income TTM
$13,270,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
353,000
Avg volume
579,602
Day's range
$3.09 – $3.37
Shares out
90,986,000
Stochastic %K
56%
Beta
0.67
Analysts
Strong Buy
Price target
$11.82

Price

Company profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical...

Show more

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
305 845 2813
Website
https://www.sab.bio
Address
777 W 41st St., Miami Beach, United States

Latest news

Stocktwits

JTebow_CWS Nov 1, 6:22 PM
$SABS Talk of the town. https://youtu.be/cKJjGqJIkpY?is=75vuuIPpro8_oyCa
0 replies
JTebow_CWS Oct 30, 3:19 PM
$SABS If you are looking for historical, non-genetically modified use of native bovine antibodies/colostrum for passive immunity in human gut infections, PubMed indexes clinical success tracking back to 1987 for rotavirus, but the 2009 paper is the landmark study for engineering cows to produce targetable human therapeutic antibodies)
0 replies
JTebow_CWS Oct 30, 3:18 PM
$SABS Understanding polyclonal This is 2009. Antigen-specific human polyclonal antibodies from hyperimmunized cattle Yoshimi Kuroiwa et al. Nat Biotechnol. 2009 Feb. https://pubmed.ncbi.nlm.nih.gov/19151699/
0 replies
JTebow_CWS Oct 30, 3:10 PM
$SABS Just sharing. Oct 4, 2016 Dr Eddie Sullivan PhD has been at this for a while now. Polyclonals are the perfect antiviral, antifungal, and adjuvant antibiotic support treatment. https://www.technologyreview.com/2016/10/04/107551/cows-engineered-with-human-genes-could-stop-our-next-disease-outbreak/
0 replies
JTebow_CWS Oct 29, 11:11 AM
$SABS Excellent education on this investment. Were early enough. https://youtu.be/7Ai-r5Z0SBg?is=znYxCR6zcevTW-BM
1 replies
JTebow_CWS Oct 29, 1:48 AM
$SABS @laaarsas Best and most through educational video. https://youtu.be/OlRwqSbOUfo?si=ETYXCIkz1z78lxXL
0 replies
laaarsas Oct 23, 4:33 PM
$SABS What is the evidence for that their drug actually would work? Seems very shaky.
3 replies
laaarsas Oct 22, 3:47 PM
$SABS This is a bit stinky right?
1 replies